# Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization

Study · id `cardio:ct-nct05347069` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05347069](<https://clinicaltrials.gov/study/NCT05347069>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05347069

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2890 participants.

## Technical summary

Registry record NCT05347069. Randomized; no masking; primary purpose prevention. Start 2022-06-14 (actual); primary completion 2030-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 2890 participants (planned count; ClinicalTrials.gov record NCT05347069, source copy `cardio:ctgov-nct05347069-2025-03-11`, retrieved 2026-10-26)
- Started: 2022-06-14 (actual) (ClinicalTrials.gov record NCT05347069, source copy `cardio:ctgov-nct05347069-2025-03-11`, retrieved 2026-10-26)
- Primary completion: 2030-03 (anticipated) (ClinicalTrials.gov record NCT05347069, source copy `cardio:ctgov-nct05347069-2025-03-11`, retrieved 2026-10-26)
- Completion: 2030-12 (anticipated) (ClinicalTrials.gov record NCT05347069, source copy `cardio:ctgov-nct05347069-2025-03-11`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT05347069, source copy `cardio:ctgov-nct05347069-2025-03-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05347069-2025-03-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without Revascularization
- Acronym: ASA-IN
- Condition: Stable Angina Pectoris
- Condition: Coronary Artery Disease
- Condition: Ischemic Heart Disease
- Intervention (Drug): Aspirin
- Intervention (Drug): No aspirin
- Lead sponsor: Takeshi Morimoto
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Stable angina (`cardio:stable-angina`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Takeshi Morimoto (`cardio:org-takeshi-morimoto`)

## Provenance

Content hash: 712909c6513e318209ca6d2e4e0769dc22bcb647995912df69369af449b585ce
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
